ORIGINAL RESEARCH article
Front. Allergy
Sec. Mechanisms in Allergy
Volume 6 - 2025 | doi: 10.3389/falgy.2025.1691886
This article is part of the Research TopicNeutrophils in Allergic DiseaseView all articles
Impact of Biologic Therapy on Blood Cell Indices and Exacerbation Risk in Severe Asthma: Predictive Value of the Neutrophil-to-Eosinophil Ratio
Provisionally accepted
- 1Kuwait University Faculty of Medicine, Safat, Kuwait
- 2Al-Rashed Allergy Center, Ministry of Health, Kuwait, kuwait, Kuwait
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Although biologic therapies have transformed the management of severe asthma, reliable blood based markers to measure treatment response and predict residual exacerbation risk remain limited. The aim of this study was evaluating routine hematologic indices as predictors of disease control and exacerbations after biologic therapy. Methods: A cohort study included 107 patients with severe asthma were assessed before and after one year of initiating biologics. Asthma control was measured with the Asthma Control Test (ACT) and Asthma Control Questionnaire (ACQ 6); exacerbations were prospectively recorded. Complete blood counts were obtained at both time points. Results: patients with severe asthma were predominantly middle-aged, obese, non-smoking women with poorly controlled asthma and elevated eosinophil counts. Biologic therapy resulted in a significant reduction in median blood eosinophil count, halving it from 480 to 240 cells/µL (p<0.001). Smaller but statistically significant decreases were also observed in total leukocyte count and neutrophil count (both p=0.02), leading to a marked increase in the neutrophil-to-eosinophil ratio (NER, p<0.001). Post-treatment, higher neutrophil counts and NER correlated with poorer asthma control, while elevated neutrophils, monocytes, and NER were significantly associated with exacerbations. Logistic regression confirmed monocytes (OR 1.03, P=0.01) and NER (OR 1.07, P=0.04) as independent predictors of exacerbation, with ROC analysis showing their significant discriminative ability (AUC 0.64-0.66). Depending on the clinical objective to rule out or confirm exacerbation risk, specific cutoffs for NER (>3.97) and monocytes (>435/µL) offered high sensitivity (~92%), or high cutoffs for NER (>50.65) and monocytes (>755/µL) offered high specificity (~91%). Conclusion: Biologic therapy significantly reduced eosinophils and altered NER in severe asthma. Prominently, elevated post-treatment neutrophils, monocytes, and particularly a higher NER, were significant predictors of poorer asthma control and increased exacerbation risk, offering clinically useful biomarkers for personalized management.
Keywords: Severe asthma, biologic therapy, neutrophil to eosinophil ratio, Monocytes, exacerbation, biomarkers.
Received: 24 Aug 2025; Accepted: 03 Oct 2025.
Copyright: © 2025 Al-Ahmad, Ali and Talat. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Mona Al-Ahmad, monaalahmad@yahoo.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.